

# Persistent function based machine learning for drug design

Xiang Liu

*Nankai University*

December 8, 2023

# Drug Discovery Process (Simplified)

## Clinical Trials

### Target Discovery

- Target identification
- Microarray profiling
- Target validation
- Assay development
- Biochemistry
- Clinical/Animal disease models

### Lead Discovery

- High-throughput Screening (HTS)
- Fragment-based screening
- Focused libraries
- Screening collection

### Lead Optimization

- Medicinal Chemistry
- Structure-based drug design
- Selectivity screens
- ADMET screens
- Cellular/Animal disease models
- Pharmacokinetics

### •Preclinical Development

- Toxicology
- In vivo safety pharmacology
- Formulation
- Dose prediction

### Phase 1

PK tolerability

### Phase 2

Efficacy

### Phase 3

Safety & Efficacy

### Launch

Indication Discovery & expansion

Discovery

Development

Use

Med. Chem. ML,

Clinical Candidates

Drugs

>450,000 distinct compounds  
~25,000 distinct lead series

~12,000 candidates

~1,200 drugs


**Time: > 10 years**

**Cost: > 2.6 billion\$**

**High failure rate**

# Drug discovery is a challenging search problem

Chemical Space



Number of possible drug-like molecules  $\approx 10^{60}$   
obeying Lipinski's rule-of-five for oral bioavailability

# AI in drug design and discovery

**nature**

Explore content ▾ About the journal ▾ Publish with us ▾ Subscribe

nature > spotlight > article

SPOTLIGHT | 30 May 2018

## How artificial intelligence is changing drug discovery

Machine learning and other technologies are expected to make the hunt for new pharmaceuticals quicker, cheaper and more effective.

Nic Fleming

**Exscientia** ABOUT PATIENT-FIRST AI PIPELINE INVESTORS & MEDIA JOIN US

View All News

### Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials

April 9, 2021

Company's technologies and drug-hunting expertise now responsible for world's first and second AI-designed drugs to enter clinical testing

Exscientia, a leading artificial intelligence (AI) driven pharmatech company, today announced the first AI-designed immuno-oncology to enter human clinical trials. The A2a receptor antagonist, which is in development for adult pancreatic advanced solid tumours, was co-invented and developed through a Joint Venture between Exscientia and Evotec. The application of Exscientia's next generation 3-D evolutionary AI-design platform as part of Centaur Chemist®.

## How AI could revolutionize drug discovery

November 16, 2022 | Video

By Alex Devereson, Christoph Sandler, and Lydia The

Artificial intelligence could help scientists develop better medicines faster—and thus improve millions of people's lives. But for that to happen, companies will need to change the way they work.

**INSIDER INTELLIGENCE** | eMarketer Search for reports, forecasts, charts, benchmarks and more Log In → Become a Client

Industries ▾ Products ▾ Insights Events Pricing About ▾

### BEHIND THE NUMBERS

Made possible by Tinuiti

Explore the rapidly changing world of digital advertising, media, commerce, and technology. Listen In ▶

## Big pharma is using AI and machine learning in drug discovery and development to save lives

Share on social: f t in ✉

AI and Machine Learning in Drug Discovery

Powerful data and analysis on nearly every digital topic

# Artificial Intelligence

Enabling machines to think like humans

## Machine Learning

Training machines to get better at a task without explicit programming

### Deep Learning

Using multi-layered networks  
for machine learning


# Feature extraction and feature learning

**“The success of machine learning algorithms generally depends on data representation...”**

***Y. Bengio, etc, “Representation Learning: A Review and New Perspectives***


**“The deep learning research aims at discovering learning algorithms that discover multiple levels of distributed representations...”**

***Y. Bengio, “Deep Learning of Representations: Looking Forward***



# Molecular Descriptors in QSAR models

More than 5000 Molecular descriptors in Quantitative Structure Activity relationship (QSAR) models.




Grisoni F, Ballabio D, Todeschini R, et al. Molecular descriptors for structure–activity applications: a hands-on approach[M]// Computational Toxicology. Humana Press, New York, NY, 2018: 3-53.

## Common chemical descriptors for QSAR/QSPR analysis

Chemical descriptors	Based on	Examples
Theoretical descriptors		
0D	Molecular formula	Molecular weights, atom counts, bond counts
1D	Chemical graph	Fragment counts, functional group counts
2D	Structural topology	Weiner index, Balaban index, Randic index, BCUTS
3D	Structural geometry	WHIM, autocorrelation, 3D-MORSE, GETAWAY
4D	Chemical conformation	Volsurf, GRID, Raptor
Experimental descriptors		
Hydrophobic parameters	Hydrophobicity	Partition coefficients (logP), hydrophobic substituent constant ( $\pi$ )
Electronic parameters	Electronic properties	Acid dissociation constant, Hammett constant
Steric parameters	Steric properties	Taft steric constant, Charton's constant

# Topological Data Analysis (TDA)

Topological invariant:  
Homology Group  
Homotopy Group  
Cohomology Ring  
Steenrod Module  
.....




Klein bottle




Torus



Double Torus




Knot




Sphere




# Topological Data Analysis---- Persistent Homology




$f_1 = 0.4$   
 $\beta_0 : 6 \quad \beta_1 : 0$




$f_2 = 0.5$   
 $\beta_0 : 3 \quad \beta_1 : 1$




$f_3 = 0.6$   
 $\beta_0 : 1 \quad \beta_1 : 1$



$f_4 = 0.8$   
 $\beta_0 : 1 \quad \beta_1 : 1$




$\beta_0 = 2 \quad \beta_1 = 1 \quad \beta_2 = 1$




# Persistent Homology Analysis of Carbon-60

(Xia, Feng, Tong & Wei, JCC, 2015)





$C_{60}$




# Biomolecular Topological Fingerprints

(Xia & Wei, IJNMBE, 2014)  
*TF for beta barrel*

*TF for alpha helix*






*Slicing method*



# TDA based machine learning models

(Pun, Lee and Xia, AIR, 2021)





# Recent progress of TDA based drug design





Guowei Wei  
MSU Foundation professor


DUD database 128374 protein-ligand/decoy pairs



Prediction correlations for 2648 mutations on globular proteins  
(Cang & Wei, PLOS CS, 2017)



Prediction RMSD of logP (star set)




# Recent progress of TDA based drug design

Drug Design Data Resource (D3R)  
Grand Challenges

Grand Challenge 2: win **14%**  
Grand Challenge 3: win **38%** while  
the **second** winner had a rate of **19%**  
Grand Challenge 4: win **50%**

***Wei Team's performance  
at D3R Grand Challenge***

## D3R Grand Challenge 2



<b>Stage 1</b>	<b>Stage 2</b>
<a href="#">Pose Predictions (partials)</a>	<a href="#">Scoring (partials)</a>
<a href="#">Scoring (partials)</a>	<a href="#">Free Energy Set 1 (partials)</a> 🏆
<a href="#">Free Energy Set 1 (partials)</a>	<a href="#">Free Energy Set 2 (partials)</a>
<a href="#">Free Energy Set 2 (partials)</a>	

## D3R Grand Challenge 3 (2017-2018)

### Pose Prediction

#### Cathepsin Stage 1A

[Pose Predictions \(partials\)](#)

#### Affinity Rankings excluding Kds > 10 μM

#### Cathepsin Stage 1

[Scoring \(partials\)](#)

[Free Energy Set](#)

#### VEGFR2

[Scoring \(partials\)](#) 🏆

#### JAK2 SC3

[Scoring](#) 🏆

[Free Energy Set](#) 🏆

#### Active / Inactive Classification

#### VEGFR2

[Scoring \(partials\)](#)

#### JAK2 SC3

[Scoring](#) 🏆

[Free Energy Set](#) 🏆

#### Affinity Rankings for Cocrystallized Ligands

#### Cathepsin Stage 1

[Scoring \(partials\)](#) 🏆

[Free Energy Set](#) 🏆

#### Cathepsin Stage 1B

[Pose Prediction](#)

#### Cathepsin Stage 2

[Scoring \(partials\)](#)

[Free Energy Set](#)

#### JAK2 SC2

[Scoring \(partials\)](#) 🏆

#### TIE2

[Scoring](#) 🏆

[Free Energy Set 2](#) 🏆

#### JAK2 SC2

[Scoring \(partials\)](#) 🏆

#### TIE2

[Scoring \(partials\)](#) 🏆

[Free Energy Set 1](#) 🏆


[Scoring \(partials\)](#) 🏆

[Free Energy Set](#) 🏆

#### Cathepsin Stage 2

[Scoring \(partials\)](#) 🏆

[Free Energy Set](#) 🏆



#### p38-α

[Scoring \(partials\)](#)

#### ABL1

[Scoring \(partials\)](#) 🏆

#### p38-α

[Scoring \(partials\)](#)

#### ABL1

[Scoring \(partials\)](#)

## D3R Grand Challenge 4 (2018-2019)



### Pose Predictions

#### BACE Stage 1A

[Pose Predictions \(Partials\)](#) 🏆<sup>1/2</sup> 🥈<sup>3/3</sup>

#### BACE Stage 1B

[Pose Prediction \(Partials\)](#) 🥈<sup>2/2</sup> 🏆<sup>1/2</sup>

### Affinity Predictions

#### Cathepsin Stage 1

[Combined Ligand and Structure Based Scoring](#) 🏆<sup>2/5</sup> 🥈<sup>2/3</sup> 🥉<sup>2/4</sup>

[Ligand Based Scoring \(No participation\)](#)

[Structure Based Scoring](#) 🏆<sup>2/4</sup> 🥈<sup>3/3</sup> 🥉<sup>3/3</sup>

[Free Energy Set](#) 🏆<sup>1/7</sup> 🥈<sup>1/7</sup> 🥉<sup>2/5</sup>

#### BACE Stage 1

[Combined Ligand and Structure \(No participation\)](#)

[Ligand Based Scoring \(Partials\) \(No participation\)](#)

[Structure Based Scoring \(Partials\) \(No participation\)](#)

[Free Energy Set \(No participation\)](#)

#### BACE Stage 2

[Combined Ligand and Structure](#)


[Ligand Based Scoring \(No participation\)](#)

[Structure Based Scoring \(Partials\) \(No participation\)](#)

[Free Energy Set](#) 🥈<sup>3/4</sup> 🏆<sup>1/4</sup>



# TDA-based learning models in SARS-Cov-2



## Mutations Strengthened SARS-CoV-2 Infectivity

**Wei's Team predicts key mutation sites in prevailing variants**

Mutations at 501 and 452 in prevailing SARS-Cov-2 variants

Jiahui Chen<sup>1</sup>, Rui Wang<sup>1</sup>, Menglun Wang<sup>1</sup> and Guo-Wei Wei<sup>1,2,3</sup>

1 - Department of Mathematics, Michigan State University, MI 48824, USA

2 - Department of Electrical and Computer Engineering, Michigan State University, MI 48824, USA

3 - Department of Biochemistry and Molecular Biology, Michigan State University, MI 48824, USA

Correspondence to Guo-Wei Wei: [wei@math.msu.edu](mailto:wei@math.msu.edu)

<https://doi.org/10.1016/j.jmb.2020.07.009>

Edited by Anna Panchenko

Received 4 June 2020;

Received in revised form 9 July 2020;

Accepted 17 July 2020;

Alpha: N501Y

Beta: K417N, E484K, N501Y

Gamma: K417T, E484K, N501Y

Delta: L452R, T478K

Epsilon: L452R

Kappa: L452R, E484Q

Omicron: N501,...

### Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity is a major concern in coronavirus disease 2019 (COVID-19) prevention and economic reopening. However, rigorous determination of SARS-CoV-2 infectivity is very difficult owing to its continuous evolution with over 10,000 single nucleotide polymorphisms (SNP) variants in many subtypes. We employ an algebraic topology-based machine learning model to quantitatively evaluate the binding free energy changes of SARS-CoV-2 spike glycoprotein (S protein) and host angiotensin-converting enzyme 2 receptor following mutations. We reveal that the SARS-CoV-2 virus becomes more infectious. Three out of six SARS-CoV-2 subtypes have become slightly more infectious, while the other three subtypes have significantly strengthened their infectivity. We also find that SARS-CoV-2 is slightly more infectious than SARS-CoV according to computed S protein-angiotensin-converting enzyme 2 binding free energy changes. Based on a systematic evaluation of all possible 3686 future mutations on the S protein receptor-binding domain, we show that most likely future mutations will make SARS-CoV-2 more infectious. Combining sequence alignment, probability analysis, and binding free energy calculation, we predict that a few residues on the receptor-binding motif, i.e., 452, 489, 500, 501, and 505, have high chances to mutate into significantly more infectious COVID-19 strains.


© 2020 Elsevier Ltd. All rights reserved.

**They discovered the mechanism of viral transmission and evolution: more infectious**


# Why is TDA so powerful ?

## Representation


Graph



Simplicial complex



Filtered simplicial complex




## Featurization


### Topological invariants

- Homology Group
- Homotopy Group
- Cohomology Ring
- Steenrod Module
- .....

Persistent barcode




Persistent diagram







Graph




Simplicial complex



Hypergraph



Super-hypergraph



Jie Wu,  
BIMSA

# Hypergraph based data representation

Grbic J, Wu J, Xia K, Wei GW. Aspects of topological approaches for data science[J]. Foundations of Data Science, 2022.


Bressan, Li, Ren, Wu. The embedded homology of hypergraphs and applications , 2016

Ren, Shiquan, et al. "Computing the Homology of Hypergraphs." *arXiv preprint arXiv:1705.00151* (2017).

Ren, Shiquan, Chengyuan Wu, and Jie Wu. "Operators on random hypergraphs and random simplicial complexes." *arXiv preprint arXiv:1712.02045* (2017).

Ren, Shiquan, and Jie Wu. "Stability of persistent homology for hypergraphs." *arXiv preprint arXiv:2002.02237* (2020).

Ren, Shiquan, et al. "A Discrete Morse Theory for Hypergraphs." *arXiv preprint arXiv:1804.07132* (2018).



# Embedded homology of hypergraph

Bressan, Li, Ren, Wu. AJM, 2019

## Definition (infimum chain complex)

Given a hypergraph  $\mathcal{H}$ , the infimum chain complex of  $\mathcal{H}$  with coefficient  $R$  is defined as

$$Inf_n(\mathcal{H}, R) = \sum \{C_n \mid C_n \text{ is a subchain complex of } R((K_{\mathcal{H}})_*) \text{ and } C_n \subset R(\mathcal{H}_n)\}$$


which is the largest subchain complex of the chain complex of  $K_{\mathcal{H}}$  that is contained in the graded modules  $R(\mathcal{H}_*)$

## Definition (supremum chain complex)


Given a hypergraph  $\mathcal{H}$ , the supremum chain complex of  $\mathcal{H}$  with coefficient  $R$  is defined as

$$Sup_n(\mathcal{H}, R) = \bigcap \{C_n \mid C_n \text{ is a subchain complex of } R((K_{\mathcal{H}})_*) \text{ and } R(\mathcal{H}_n) \subset C_n\}$$

which is the smallest subchain complex of the chain complex of  $K_{\mathcal{H}}$  that contains  $R(\mathcal{H}_*)$  as a graded modules.



Hypergraph  $H$



Associated simplicial complex  $K_H$

## Proposition

Given a hypergraph  $\mathcal{H}$ , the homology of the infimum chain complex of and supremum chain complex of  $\mathcal{H}$  with coefficient  $R$  are isomorphic.

## Definition (Hypergraph embedded homology)

Given a hypergraph  $\mathcal{H}$ , the  $n$ -th embedded homology of  $\mathcal{H}$  with coefficient  $R$  is defined as

$$H_n(\mathcal{H}, R) = H_n(Sup_*(\mathcal{H}, R)) = H_n(Inf_*(\mathcal{H}, R))$$

$$C_0 = Z\{\{0\}, \{1\}, \{2\}, \{3\}, \{4\}\}$$

$$C_1 = Z\{\{0,1\}, \{2,3\}, \{2,4\}, \{3,4\}\}$$

$$C_2 = Z\{\{0,1,2\}\}$$


$$A_0 = Z\{\{0\}, \{1\}, \{2\}, \{3\}, \{4\}\}$$

$$A_1 = Z\{\{0,1\}, \{0,2\}, \{1,2\}, \{2,3\}, \{2,4\}, \{3,4\}\}$$

$$A_2 = Z\{\{0,1,2\}\}$$

$$\rightarrow A_3 \xrightarrow{\partial_3} A_2 \xrightarrow{\partial_2} A_1 \xrightarrow{\partial_1} A_0$$

$$S_n = C_n + \partial_{n+1}(C_{n+1}), I_n = C_n \cap \partial_n^{-1}(C_{n-1})$$



$$I_0 = Z\{\{0\}, \{1\}, \{2\}, \{3\}, \{4\}\}$$

$$I_1 = Z\{\{0,1\}, \{2,3\}, \{2,4\}, \{3,4\}\}$$

$$I_2 = 0$$

$$S_0 = Z\{\{0\}, \{1\}, \{2\}, \{3\}, \{4\}\}$$

$$S_1 = Z\{\{0,1\}, \{2,3\}, \{2,4\}, \{3,4\}, \partial\{0,1,2\}\}$$

$$S_2 = Z\{\{0,1,2\}\}$$

$$H_0^s = Ker(\partial_0^s) / Im(\partial_1^s)$$

$$= S_0 / Im(\partial_1^s)$$

$$= Z\{\{0\}, \{1\}, \{2\}, \{3\}, \{4\}\} / Z\{\{1\} - \{0\}, \{3\} - \{2\}, \{4\} - \{2\}, \{4\} - \{3\}\}$$

$$= I_0 / Im(\partial_1^i)$$

$$= Ker(\partial_0^i) / Im(\partial_1^i)$$

$$= H_0^i$$

$$H_1^s = Ker(\partial_1^s) / Im(\partial_2^s)$$

$$= Z\{\{3,4\} - \{2,4\} + \{2,3\}, \partial\{0,1,2\}\} / Z\{\partial\{0,1,2\}\}$$

$$= Z\{\{3,4\} - \{2,4\} + \{2,3\}\}$$

$$= Ker(\partial_1^i) / Im(\partial_2^i)$$

$$= H_1^i$$

$$H_2^s = Ker(\partial_2^s) / Im(\partial_3^s)$$

$$= Ker(\partial_2^s)$$

$$= 0$$


$$= Ker(\partial_2^i) / Im(\partial_3^i)$$

$$= H_2^i$$


Liu, Wang, Wu, Xia,  
BIB, 2021

# Protein-ligand interaction modeled as hypergraph


## Hypergraph-based models



## Hypergraph-based filtration






## Bipartite graph VS Hypergraph



# Benchmark testing with PDBbind datasets

*Model setting:*  
*homology vectors*  
+  
*Gradientboostingtree*



# Persistent function based machine learning


## Data

## Representation


## Featurization

## Learning


Protein




Simplicial complex: Neighborhood complex, Dowker complex,...




Polyhedral complex: Hom complex...




Hypergraph, Super-hypergraph ...




Algebraic representation: face ring...




Protein-ligand complex




Protein-protein complex




Persistent homology




Persistent Spectral





Persistent Tor-algebra



Machine learning: Random Forest, GBT, SVM,...



Deep learning: Convolution neural network,...



*Thank You!*